News

BMJ4d
2023 ACR/EULAR antiphospholipid syndrome classification criteria
Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of ...
BMJ5d
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
Correspondence to Dr Zachary Scott Wallace, Division of Rheumatology, Allergy, and Immunology and Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General ...
BMJ6d
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
Objectives To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or vice versa, in patients with rheumatoid arthritis with non-response or incomplete-response to the ...
BMJ7d
Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
Correspondence to Eloisa Bonfa, Rheumatology Division, Universidade de Sao Paulo Faculdade de Medicina, Sao Paulo 04746-070, Brazil; eloisa.bonfa{at}hc.fm.usp.br Objective To evaluate the effect on ...
BMJ7d
Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines
Correspondence to Professor Zhuoli Zhang, Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China; zhuoli.zhang{at}126.com We conducted a real-world survey ...
BMJ7d
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Correspondence to Dr Robert Spiera, Department of Medicine, Hospital for Special Surgery, New York, NY 10028, USA; spierar{at}hss.edu There is a paucity of data on the effect of antirheumatic drugs on ...
BMJ7d
Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases
3 Rheumatology unit, Department of Medicine, Karolinska Hospital, S-171 76 Stockholm, Sweden 4 Department of Public Health Sciences, Karolinska Institutet, S-171 77 Stockholm, Sweden Correspondence to ...
BMJ8d
Local and systemic glucocorticoid metabolism in inflammatory arthritis
Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK Background: Isolated, primary synovial fibroblasts generate active glucocorticoids through ...
BMJ9d
Can solid-phase assays replace immunofluorescence for ANA screening?
Correspondence to Dr Nicola Bizzaro, Laboratory of Clinical Pathology, San Antonio Hospital, Tolmezzo–Azienda Sanitaria Universitaria Integrata di Udine, Tolmezzo 33028, Italy ; ...
BMJ10d
Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Correspondence to Dr Andrew I Rutherford, Academic Rheumatology, NIHR Biomedical Research Centre at Guy’s and St Thomas' NHS Foundation Trust and King’s College, Weston Education Centre, King’s ...
BMJ10d
Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients
Objectives There is little known about the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). We examined epidemiological characteristics associated with ...
BMJ10d
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
2 Rheumatology Service, Department of Medicine, Hospital Clinico Universitario, Medical School, Universidad de Santiago de Compostela, Santiago de Compostela, Spain Background: Mortality is increased ...